Five things for pharma marketers to know: Monday, June 27, 2016

1. Six former FDA commissioners said the agency should no longer be a part of the Department of Health and Human Services. The former commissioners told attendees at the Aspen Ideas Festival that giving the FDA more autonomy would improve public health. (STAT)

2. Sanofi and Boehringer Ingelheim have agreed to an asset swap valued at $25 billion. Sanofi will trade its Merial animal-health business for BI's consumer-health business. BI will also pay Sanofi €4.7 billion. (Bloomberg)

3. An FDA panel will vote on whether Eli Lilly's and Boehringer Ingelheim's diabetes drug Jardiance reduces the risk of cardiovascular death on Tuesday. (Reuters)

4. A strategic generics alliance between Dr. Reddy's Laboratories and GlaxoSmithKline has ended. The 2009 deal was formed to develop and market certain generic products in Latin America, Africa, the Middle East, and Asia-Pacific markets. (Livemint)

5. ICYMI: Bayer has distanced itself from a Brazilian aspirin ad that some have criticized as sexist. The company said it will not allow the campaign to be run any longer. The advertisement won a Bronze Cannes Lion. (Adweek)


Next Article in Legal/Regulatory